Trial Profile
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects With Severe Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Darapladib (Primary)
- Indications Atherosclerosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 28 Apr 2015 New trial record